Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival

Exp Hematol. 2008 Apr;36(4):464-72. doi: 10.1016/j.exphem.2007.12.010. Epub 2008 Feb 8.


Objective: Bone marrow (BM) Th1 populations can contribute to graft-vs-leukemia responses. Granulocyte/granulocyte macrophage colony-stimulating factor (CSF)-mobilized peripheral blood progenitor cells (PBPC) have become widely accepted alternatives to BM transplantation. T cells coexpressing natural killer cell proteins (NKT) include a CD1d-reactive subset that influences immunity by rapidly producing large amounts of Th1 and/or Th2 cytokines dependent upon microenvironment and disease. There are two types of CD1d-reactive NKT. iNKT express a semi-invariant T-cell receptor-alpha. Other noninvariant CD1d-reactive NKT from BM and liver produce large amounts of interleukin-4 or interferon-gamma, respectively, and within the intestine can be biased in either direction. Recent data suggests that NKT might contribute to clinical benefits of PBPC.

Materials and methods: To address these issues, we phenotypically and functionally studied PBPC NKT.

Results: Similarly to BM, NKT-like cells were common in allogeneic and autologous PBPC, there were relatively few classical iNKT, but high CD1d-reactivity concentrated in NKT fractions. Significantly, PBPC CD1d-reactive cells were relatively Th1-biased and their presence was associated with better prognosis. Granulocyte CSF treatment of BM to yield PBPC in vivo as well as in vitro Th2-polarizes conventional T cells and iNKT. However, granulocyte CSF treatment of BM in vitro produced Th1-biased NKT, providing a mechanism for opposite polarization of NKT from BM vs PBPC.

Conclusions: These results suggest distinct Th1 CD1d-reactive NKT cells could stimulate anti-tumor responses from those previously described, which can suppress graft-vs-host disease.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Antigens, CD1 / immunology*
  • Antigens, CD1d
  • Cell Separation
  • Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology
  • Hematopoietic Stem Cells / cytology
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / immunology*
  • Hodgkin Disease / immunology*
  • Humans
  • Immunophenotyping
  • Killer Cells, Natural / cytology
  • Killer Cells, Natural / immunology*
  • Lymphoma, Non-Hodgkin / immunology*
  • Middle Aged
  • Multiple Myeloma / immunology*
  • Stem Cell Transplantation
  • Survival Rate
  • Th1 Cells / cytology
  • Th1 Cells / immunology*
  • Treatment Outcome


  • Antigens, CD1
  • Antigens, CD1d
  • CD1D protein, human
  • Granulocyte-Macrophage Colony-Stimulating Factor